AASLD: HCV Outcomes Under Scrutiny Treatment now 'predictably'

This topic has 2 replies, 3 voices, and was last updated 8 years ago by Dr James.

Viewing 3 posts - 1 through 3 (of 3 total)

Author

Posts
11 November 2016 at 1:14 am #24249
Tommy
- Topics: 16
- Replies: 88
- Total: 104
- Guardian Angel
@tommy
http://www.medpagetoday.com/meetingcoverage/aasld/61333
Meeting Coverage
AASLD: HCV Outcomes Under Scrutiny
Treatment now ‘predictably’ good in trials but what about real world?

Genotype 1A
ALT 473
AST 226
Virus Load 3,119,030
Results as of May-2016
5 week viral load/undetected as of 12/02/2016
Liver Biopsy Results from Feb 2013
Portal/Periportal chronic inflammation and mild interface hepatitis (Grade 2)
Focal Lobular chronic inflammation (Grade 1)
Portal/Periportal fibrosis (stage 1-2 trichrome and reticulin stains utilized)
Negative Iron stains.
11 November 2016 at 4:51 am #24254
Greedfighter
- Topics: 28
- Replies: 582
- Total: 610
- Guardian Angel
@greedfighter
Great post Tommy,

Too bad all these articles are by corrupt or ignorant people. The “real world” issue is most people are being denied treatment.

Most people in the world have access to generic medications they can buy and import. I actually realized just today, that by accessing generics, that cost me $1400, I saved a lot of money. Had my insurance approved me for treatment, I would have paid at least $4500 co-pay. What a win
11 November 2016 at 6:23 am #24257
Dr James
- Topics: 264
- Replies: 1,968
- Total: 2,232
- Guardian Angel
@fixhepc
This article from MD Live is talking about an article from the Lancet – which is the number 1 medical journal in the world.

The title: Should Generic DAAs Be More Widely Imported?

The conclusion: Yes

http://www.hcplive.com/medical-news/should-generic-daas-be-more-widely-imported

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32051-7/fulltext

YMMV
Author

Posts

Viewing 3 posts - 1 through 3 (of 3 total)

You must be logged in to reply to this topic.